HUE035520T2 - Interferon alfa antitestek és felhasználásuk - Google Patents
Interferon alfa antitestek és felhasználásuk Download PDFInfo
- Publication number
- HUE035520T2 HUE035520T2 HUE11183602A HUE11183602A HUE035520T2 HU E035520 T2 HUE035520 T2 HU E035520T2 HU E11183602 A HUE11183602 A HU E11183602A HU E11183602 A HUE11183602 A HU E11183602A HU E035520 T2 HUE035520 T2 HU E035520T2
- Authority
- HU
- Hungary
- Prior art keywords
- antibody
- ifn
- seq
- antibodies
- íció
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/249—Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1021—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against cytokines, e.g. growth factors, VEGF, TNF, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Transplantation (AREA)
Claims (12)
- ékmbédíbidi igönypödtek I. izolált snîi interiertm Old ;mmoUombl:$ imibesk vagy aimak arbígérikólő ré:;?e, aesOyOoa & következők benne fögláitoak: (si) oebé.··: iáneő vazlábtíts tégló CPR. i, amely tarbdmszz.& bEQ IP NO: 1 konzervatív mődositását, a módosítás tmaintaz egy, kettő vagy bât om konzervatív antiftosav szubsztitúciót; (b) nebéz lémm variables regio CDR2, amely tartalmazza. SCO 10 NO; 4 konzervaCv módositáséi, a tnódositás -taitaUnaz egy, kettő vagy három konzervatív aminosav szubsziiiúeiót; (c) nehéz láncú variábilis régió CORN ersmly rartahnaz. SEQ ID NO: ?-;, (dl könnyű iám:é variábilis régal CDRÍ. atneiv tartalmazza SEQ ID NO: lő konzervatív módosítását, a módosítás tartalmaz agy, kettő vagy hármd konzervatív asmbesav azebszlöóNót; te» konrs»» dt\»' »«oNl>> í<.Î..Î..··: V BR,\ ,í»i>\, swir»a'\t btII» \P ä' Ρ'»,ο»\»θ' módosítását, a módosítás tartalmaz egy, keltő vagy három konzervatív smmosav szubsztltôcîôt; és v»t kem»\a Pere \a»,ui'th' regje r ORR mned, »«;»;»»,» ,,» OQ 10 V' ’»' Ov.’ena’i' nuxiositását, a módosítás tartalmaz egy, kettő vagy három konzervatív aminosav szubsztitúciót; és ahol az antitest. vagy annak antigénkotö része, mh»b»tália a következőket· hmphoblastotsl IFN, ÍPNoó, ÍPNsCb, ÍPNoÉm ICNirl, Leukocyte IFN, íFNölb, ICNolö. W«8, IENíO, IFNoié, ICNdí?, IFN«? ês IFN«4, de nem isddbiráiis IFN béta vagy IFN omega biológiai aktivitását. X Az I. igénypont szerinti antitest·, vagy annak sidlgsokéRő része, amelybe« a kövelkezók bonne foglaltnak; (as nehéz láncú variábilis régió CDRI, amely tartalmazza S£Q ID NO: I kotszervatlv tnődosliásái, a módósíids izrmbis«.··: nem több, mint kettő konzervatív amioosav szobsxíitúelói; t b) nehéz láncú variábilis régió CDRX. amely tmtsksazza SCO ÍD NO; 4 konzervatív módosítását, a módosítás tartalmaz nem több, mi at kettő konzervaslv aminosav szubsztitúciói ; t·,: ) nehéz láncú variábilis Oglö CDR3, amely:· tartalmazza SCQiD NO: 7mE (dl könnyű lámát variábilis régió ODRI, amely tartalmazza SEQ 10 NO. 10 konzervatív módosítását, a módosítás tartalmaz -nem több, álhit kettő kongé'rvátiv aminosav -szubszíiUlöfőti és) könnyít lém:d variábilis régió C0R2, amely tartalmazza SEQ ID NO; is kodzervadv möóosítésóí, a rdóbösétas imndsmz nem Óbb, mintkedökódzervadv aminosav szebeetitóelöí; és V» Ο»-»'» h«eo wurio .rgm tDR', »mei». »,>» dn»,.-', Ό 0 IP \»p I« Von\·^.»,λ mmk\'»t.)s·»! s ntixb'dtas mttaimaz nem robb, nom k,nt·' »Onee»s.div vemo^er \ζ»»0Μ»5«Ο5οχ. 3. A 2. igéd)'pont szerinti antitest, vagy annak ermgéoke;« résem .xnelybeo a következők beérő ib»d,tlt»»,äk: tísi nőhöz lóíKó vxriébRis régió CDSE érdéig-.tariaiinazza SCO IP NO: I ‘mr/ervebv módosítását; a módosítás termmmz egy konzervatív amsdóSáv rzebvöééemu (b) nehéz lénél; variábilis régió C0R2, améiy tártaháarizí? SEQ 10 NO: 4 konzervatív mődoriósék a módosítás tartalmaz egy konzervatív smmosav serjbéDliösriói; (el sebé/ Sáísöís variábilis régió CPRX rddély tártólmazeg sEQ ID NO: 7-el: {dï könriyo lancé variábilis régió ODRI, amely tari&b-aszsa Stíl) 1D NO: 10 konzervatív rnédositását, a módosítás iMahaâz· egy konzefvntjy asnirtpsav szobszítíácstííi :c) könnyű: isncö variábilis régió GDR2, snneiy tartaitoazza: Si'Q lö ÁO: 15 koazervstiv módösliásál, s módosítás nvraármz égy konzervatív antínösav sz-ibsziittíciótí <>. (!) ktínnuí ionén \onnh»m. regív t PRE .tna'U m{»a:snoa,-o Sl'O Nt’ io kvnrenc.nr ntOdosirását, a rnédosiiás tartalmaz egy konzervatív amlnosav »zobsztítóeiót, 4, Í?X '» » ' y V X ' ! V i t V C X X »\ X (a) neiséz lánen vârlâbilè; régiós. amely tartalmaz mrnrsosav szekveóéíál, ato&iiy 50% -g’Da-batt 0x ! ·. Λ V \ I \< ' Λ' 1< ! < >\ X xVx >x >' 1 ? 1 \ΛΟΟ'.»> k.fx, \ai eb 'V »' !'>í ’ »x ' ,<χ",»!θχ, m»»U'<tx ' X' '»», ,. \»\íx A"-‘ homológ aminosav szekvenciával, arnelv ki van választva a következőből: SEQ H> NO: 22 ; és, ahol az t ' 1 'X X l <'t \ '< , >·. 'M' X \ x < '» > X » ! 0' Xx ' X Hm ')! I, χΙ I ! \»' I \ i\'! \ V , ! χχΧ X i \ t \t, > î\ X I \ \ \ ' \x t ’ \ X ixii »"< ' ixtí- » 4 \ \ X 'j'x i \ x ! x\ » é c ' ».», ,-:·. 'X ' va
- 5. Az I-i. igétsyporacik bármelyike szerinti: aniiléstí vsgy ;mnak amigétikníó részé, ahol az ántírevt initíbiláljá €059 vagy M MG Osztály I IkN ähal indnká il téiiileii ezprasszigiat patáiériás vér egymagvá xejtjc’n ó. Az 1-4, igértypotttók bármelyike szerkói arabest, vagy annak ántígénkőtö része, ahol az antitest, ínhihóálja ití 10 il-'N által indukált exptessziöjâi parlierst;,; vér egym&gvá sejtjei által.
- 7. Az 1-4. "igénypontok bárínelyíké szérirttí ántísést:, vagy annak artrlgéokbiö része, ahol ez aótbest aonbnxiga xz»xz»x m v, ionos <a ; tbr mon»xn ' p't i' > pt.»z»n.» omd kxOs einen χ|<(.,η nikax \» g t-yde-teoet. k. Az 1-4. igénypontok bártnölylke szoristí antitest, vagy sortok ántígénköiő része, áitíéíy emberi antitest;
- 9, Az 1-4; igénypontok 'bármelyike szatírái u'»\,s vagy annak ántígétíkőtő. része, amely im nem» zák vagy ki méta· antitest. Ki: Az előző igénypontok bármelyike szerinti arákesi vagy annak antigébköíö részé. tstnely IgG I vagy íg€54 antitest.
- 11, Az i-IO. igénypontok bármelyike szerinti antitest vagy annak antigénknin része, ahol az gntígéokátéí rész l áb arttítest iragmeni.
- 12, Az i-IO. igénypontok bármelyike szerinti tuti best vagy .annak antígénkötó részt:, ahol az antígébköíő rész tgysztrts láned aíititest tsei-y y 13, ' pe ü. ,< X» eb ( s >1 » » : «.><,'» \ 'x m ·,ό\ ' i\ \ k χ x > 5» x < » s , », » , Î , \t ' X x\ X , X X xt i X ,X> X ! X< Sí X» , » » 14 A x x χρ< \ < \·,><! »'x » x , x" el, 15. tn:nnn»k''m!,g,xo, .»»orN tormimvza ο; ,Ί? ',όι«’,«'»!»»»'». hartm.ΐχ»Se s\ »m aouo.mt sogv astaak aatígénkőiő tvazót. amely terápiás szo rke.··- χ-aa kapesoiva. 16. A 15:. igénypont szerinti imtnonkonjugâr, aboi & terápiás szer e-Howin» |7. Ä 'x mees pmn x.e’i.it! nn noiOm, »y.»' » nA χ, οό,-»,»' χ x» ΐ,Μο »vor-..'teg r§. Kompozíció, amely éarréímazza a ÍS, igénypont szerinb itmtmrdmryogáfób és gyógyszerészotiieg elfogadható hordózőíntya^ot.
- 19. Bispeeifikus molekula, amely tartalmazza az M2. igénypontok bármelyike axerlntt antitestet, vagy ' V,; <mn "U<> ' u s " nsruk n\ on< s ' \ u \a ,.--.<·. u u w kmb< <' \ ' s spec if iékása van mást az áréitosbiek, vágy aanak andgénkôtô részének.
- 20, Kompozíció, amely tartalmazza a 19. igénypont szerinti bispeeifikus niolekniát, és gyógyszerés zed leg eitögsdhaip honiozóaovagot. 21, · izolált nnkléinsav nmlnkbld». aidély kódoló az ßl2- Igénypontok fetnnélyik« szorlréi wltéslet, zagy annak antígénkdtö részét,
- 22. Fxptesázki vektor, amely tartalmazzá az. 21. igényperé szMnb nukielnsav nsoiekulál.
- 23. Host seit. amely tattaínmzirés 32. Igényrérét szerinti expresszié vektort.
- 24, Trsnszgén égéi-, -amely tartalmaz emberi Irntmmgiohoiin nehéz és körntyn láncö Sranszgéneket, rémi az eger expnusMjn zz M?, igénypontok hurmeíukt rzctmt« tnrèures, gr anttsk aréreem.ue részéi:. 23, 11 zzidóma, amely a 24- ígényporé s/esiml egérixll van .készítve, állói a hiPridóma termeli az vsnt'U'síré, rags ao".5\oré mnkU" re-res
- 26. In vitro eljárás anil .IFN alfa antitest, vagy annak anngénkőtő része előállítására, amelyben a kővetkezők benne, fbglaknafc; (1) antitest, vagy annak antígéskőtö része rendelkezésre boesréása, amely tartalmazza,· (s)-nehéz láncú variábilis régió CDR 1, amely tartalmazza SEQ li> NO: Rét; fb) nehéz íáocá variábilis régir:· ÇDR2. atnely tartalmazza SEQ ÍD NO: 4-et; (el nehéz lámái veriélpiis régió <MR2, amely tartniniazzn SI .Q ÍR NO: 7-0', (d) könnyű láncé variábilis régió CORE amely tartalmazza SEQ ID NO 10-eg (é) könnyé lázáré variábilis régió CDR2, amely tmtaitnazza SEQ iß NO: 13-ad és (ß könnyű láncé vat labilis régié CDR3, amely tartalmazza SI2Q ID NO: iö-ré. (il) legalább egy anmmsav maradék rnegvélïoztarésa legalább egy variábilis regién belök bogy Ngslább egy megváltoztatott antitestet. vagy annak amigénkötó részét alkossunk, amely tartalmaz legalább egy amidősáv megváliöztatáíiE Ijü) a söegyáíiözpáótt antitest, vagy annak antigénkőlő része expresszálásál nemproteint; (tv) értékéljök a mégvéköZiátöit ánbrest vagy annak ándgénkótö .része kötési aktivitáséi ; és p-s azonosítok megváltoziatréi antitestet, vagy annak áréigénkőlö részét, áráély speOdkásán köt ÍFN ulfá-hoz. inhlbhéijá a kővetkezőket: lympbobíastoid IFN, íFN«ó. IF"N«2b. IFNMa. IfNoí, Leukocyte ÍFN. ÍFNtiiö, íFNtcíO, HNtdk ίΕΝηό, ÍFNect4, IFNöí?, ÍFN.«? és íFNa4, ele nem ínhíhitáljs: IFN béta usré il 0 omega bmlom n Mon,taré, 27. £r vivo eljárás miertbros alla biológiai aktivitásának Inhibitáiására, amely tartalmazza lstetiéron: állá kontakiálásái az E-12. igénypontok bármelyike szerinti antitesttel vagy annak antigéstkötö részéivel, he,'\ íz mtertenm ,dO moMmn ,όονηονι m'mb ;O$ i r,sn. :?8. .Az ML ieeaspeaíMMríaelvlke szerinti antitest. vagy attaak antígMkötö része, lethaszstäife» eljárásba« isáeríerM sila által közvetített betegség vagy reábeiíeaesség kezelésére sláeybaa, aklttsiv erre sköksége vet;. alföí a besegle;: vagy readeileeesség szlszíMtás Itipys esytiieieiböstisy sviesOsk stáiiílpléx. ' s *\ l ' ? < ' X ! Jl i p ' < μ » t } nsn thyroiditlSi riwmkskí ï> \ ‘ V IK U V p s ' \ ' « í <. K ' ' ’ >f Ή \ i S ! t \
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52875703P | 2003-12-10 | 2003-12-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE035520T2 true HUE035520T2 (hu) | 2018-05-28 |
Family
ID=34699898
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE11183602A HUE035520T2 (hu) | 2003-12-10 | 2004-12-10 | Interferon alfa antitestek és felhasználásuk |
Country Status (19)
Country | Link |
---|---|
US (6) | US7741449B2 (hu) |
EP (2) | EP2418220B1 (hu) |
JP (2) | JP5047626B2 (hu) |
KR (2) | KR101151477B1 (hu) |
CN (2) | CN102344491B (hu) |
AU (2) | AU2004299833B2 (hu) |
CA (1) | CA2546054C (hu) |
DK (2) | DK1711207T3 (hu) |
ES (2) | ES2641831T3 (hu) |
HK (1) | HK1095765A1 (hu) |
HU (1) | HUE035520T2 (hu) |
IL (1) | IL175586A (hu) |
IN (1) | IN2009KN02655A (hu) |
LT (1) | LT2418220T (hu) |
NZ (1) | NZ547157A (hu) |
PL (2) | PL2418220T3 (hu) |
PT (2) | PT1711207E (hu) |
SI (2) | SI1711207T1 (hu) |
WO (1) | WO2005059106A2 (hu) |
Families Citing this family (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR0206364A (pt) * | 2001-01-09 | 2005-08-16 | Baylor Res Inst | Métodos para tratar doenças auto-imunes em um indivìduo e testes diagnósticos in vitro |
ES2313039T3 (es) * | 2003-04-23 | 2009-03-01 | Medarex, Inc. | Composiciones y procedimientos para la terapia de enfermedad inflamatoria intestinal. |
AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
HUE035520T2 (hu) | 2003-12-10 | 2018-05-28 | Squibb & Sons Llc | Interferon alfa antitestek és felhasználásuk |
AU2005258077C1 (en) | 2004-06-21 | 2012-10-25 | E. R. Squibb & Sons, L.L.C. | Interferon alpha receptor 1 antibodies and their uses |
CN101056654A (zh) * | 2004-10-07 | 2007-10-17 | 苏黎士大学 | 用于预防和治疗银屑病的i型干扰素阻断剂 |
US8080638B2 (en) | 2005-02-10 | 2011-12-20 | Baylor Research Institute | Anti-interferon alpha monoclonal antibodies and methods for use |
US7888481B2 (en) * | 2005-02-10 | 2011-02-15 | Baylor Research Institute | Anti-interferon alpha monoclonal antibodies and methods for use |
AU2006232287B2 (en) | 2005-03-31 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
WO2007002543A2 (en) | 2005-06-23 | 2007-01-04 | Medimmune, Inc. | Antibody formulations having optimized aggregation and fragmentation profiles |
US8609816B2 (en) | 2005-12-08 | 2013-12-17 | Medarex, L.L.C. | Human monoclonal antibodies to O8E |
EP4001409A1 (en) | 2006-03-31 | 2022-05-25 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
EP2009101B1 (en) | 2006-03-31 | 2017-10-25 | Chugai Seiyaku Kabushiki Kaisha | Antibody modification method for purifying bispecific antibody |
DK2557180T3 (da) | 2006-04-24 | 2014-09-15 | Genentech Inc | Fremgangsmåder til påvisning af autoimmune lidelser |
JP2010506842A (ja) | 2006-10-16 | 2010-03-04 | メディミューン,エルエルシー | 半減期が短縮された分子、その組成物および使用 |
CN101678100A (zh) * | 2006-12-06 | 2010-03-24 | 米迪缪尼有限公司 | 治疗***性红斑狼疮的方法 |
JP2010512315A (ja) * | 2006-12-06 | 2010-04-22 | メディミューン,エルエルシー | インターフェロンα誘導性薬力学的マーカー |
EP2077859A4 (en) * | 2007-03-30 | 2010-11-24 | Medimmune Llc | ANTIBODY FORMULATION |
US20100261172A1 (en) * | 2007-05-03 | 2010-10-14 | Medimmune, Llc | Interferon alpha-induced pharmacodynamic markers |
EP2068924A4 (en) * | 2007-05-03 | 2011-07-20 | Medimmune Llc | INTERFERON ALPHA INDUCED PHARMACODYNAMIC MARKERS |
RU2519227C2 (ru) | 2007-05-14 | 2014-06-10 | Медиммун, Ллк | Способы снижения числа эозинофилов |
PE20090711A1 (es) | 2007-09-26 | 2009-07-15 | Chugai Pharmaceutical Co Ltd | Region constante de anticuerpo mutante |
ES2595638T3 (es) | 2007-09-26 | 2017-01-02 | Chugai Seiyaku Kabushiki Kaisha | Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR |
CN101909444B (zh) | 2007-11-05 | 2013-09-18 | 米迪缪尼有限公司 | 硬皮病治疗方法 |
WO2009070642A1 (en) * | 2007-11-28 | 2009-06-04 | Medimmune, Llc | Protein formulation |
EA201000910A1 (ru) * | 2007-11-30 | 2011-04-29 | Бристоль-Мейерз Сквибб Компани | Конъюгат "моноклональное антитело против в7н4/лекарственное средство" и способы его применения |
US8357782B2 (en) * | 2008-03-21 | 2013-01-22 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Monoclonal antibodies specific for human interferon-alpha subtype alpha 8 |
WO2009135861A2 (en) | 2008-05-07 | 2009-11-12 | Novo Nordisk A/S | Humanized antibodies against human interferon-alpha |
TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
US20110256149A1 (en) * | 2008-10-09 | 2011-10-20 | Medimmune, Llc | Antibody formulation |
JP5717624B2 (ja) | 2009-03-19 | 2015-05-13 | 中外製薬株式会社 | 抗体定常領域改変体 |
JP5787446B2 (ja) | 2009-03-19 | 2015-09-30 | 中外製薬株式会社 | 抗体定常領域改変体 |
EP3309168A1 (en) * | 2009-08-06 | 2018-04-18 | F. Hoffmann-La Roche AG | Method to improve virus removal in protein purification |
HUE032917T2 (hu) | 2009-09-03 | 2017-11-28 | Medimmune Llc | 1-es típusú interferon diagnosztikum |
WO2011037158A1 (ja) | 2009-09-24 | 2011-03-31 | 中外製薬株式会社 | 抗体定常領域改変体 |
EP2543730B1 (en) | 2010-03-04 | 2018-10-31 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
GB201012784D0 (en) * | 2010-07-29 | 2010-09-15 | Ucb Pharma Sa | Method |
PL3721880T3 (pl) | 2010-09-01 | 2022-05-23 | Thomas Jefferson University | Kompozycja i sposób naprawy i regeneracji mięśni |
KR102099580B1 (ko) | 2010-11-17 | 2020-04-10 | 추가이 세이야쿠 가부시키가이샤 | 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자 |
KR20230005405A (ko) | 2011-02-25 | 2023-01-09 | 추가이 세이야쿠 가부시키가이샤 | FcγRIIb 특이적 Fc 항체 |
BR112013030242A2 (pt) * | 2011-05-25 | 2016-12-06 | Medimmune Llc | método de tratamento de um distúrbio autoimune em um sujeito humano |
WO2013048243A1 (en) | 2011-09-29 | 2013-04-04 | Apo-T B.V. | Multi-specific binding molecules targeting aberrant cells |
TW201817744A (zh) | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之FcRn結合域的治療性抗原結合分子 |
JP6322411B2 (ja) | 2011-09-30 | 2018-05-09 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
KR20140100532A (ko) | 2011-11-30 | 2014-08-14 | 추가이 세이야쿠 가부시키가이샤 | 면역 복합체를 형성하는 세포내로의 운반체(캐리어)를 포함하는 의약 |
WO2013101771A2 (en) | 2011-12-30 | 2013-07-04 | Genentech, Inc. | Compositions and method for treating autoimmune diseases |
CA2860914A1 (en) | 2012-01-13 | 2013-07-18 | Apo-T B.V. | Aberrant cell-restricted immunoglobulins provided with a toxic moiety |
EP4310191A3 (en) | 2012-06-14 | 2024-05-15 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule containing modified fc region |
AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
TW202340236A (zh) | 2012-08-24 | 2023-10-16 | 日商中外製藥股份有限公司 | FcγRIIb特異性Fc區域變異體 |
KR102249779B1 (ko) | 2012-12-27 | 2021-05-07 | 추가이 세이야쿠 가부시키가이샤 | 헤테로이량화 폴리펩티드 |
MX366124B (es) * | 2013-03-15 | 2019-06-27 | Janssen Biotech Inc | Anticuerpos antagonistas del interferón alfa y omega. |
CA2908350C (en) | 2013-04-02 | 2023-08-08 | Futa Mimoto | Fc region variant |
AU2014286131C1 (en) * | 2013-07-03 | 2020-02-13 | Immunoqure Ag | Human anti-IFN-alpha antibodies |
PL3508502T3 (pl) | 2013-09-20 | 2023-07-17 | Bristol-Myers Squibb Company | Kombinacja przeciwciał anty-lag-3 i przeciwciał anty-pd-1 w leczeniu raka |
WO2015046467A1 (ja) | 2013-09-27 | 2015-04-02 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
TWI713453B (zh) * | 2014-06-23 | 2020-12-21 | 美商健生生物科技公司 | 干擾素α及ω抗體拮抗劑 |
MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
KR101655567B1 (ko) | 2014-11-10 | 2016-09-07 | 현대자동차주식회사 | 하이브리드 차량의 구동 제어 장치 |
CR20170251A (es) | 2014-12-19 | 2017-07-19 | Chugai Pharmaceutical Co Ltd | Anticuerpos anti-c5 y métodos para su uso |
CA2963760A1 (en) | 2014-12-19 | 2016-06-23 | Yoshinao Ruike | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
WO2016112497A1 (zh) * | 2015-01-13 | 2016-07-21 | 中国人民解放军军事医学科学院生物工程研究所 | 人源抗人α干扰素抗体及其应用 |
JP2018510842A (ja) | 2015-02-05 | 2018-04-19 | 中外製薬株式会社 | イオン濃度依存的抗原結合ドメインを含む抗体、Fc領域改変体、IL−8に結合する抗体、およびその使用 |
WO2016136933A1 (ja) | 2015-02-27 | 2016-09-01 | 中外製薬株式会社 | Il-6関連疾患治療用組成物 |
WO2016159213A1 (ja) | 2015-04-01 | 2016-10-06 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
MA45488A (fr) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | Procédés, kits et appareil de culture de cellules |
US10222547B2 (en) | 2015-11-30 | 2019-03-05 | Corning Incorporated | Flame-retardant optical fiber coating |
JP7141336B2 (ja) | 2015-12-25 | 2022-09-22 | 中外製薬株式会社 | 抗ミオスタチン抗体および使用方法 |
US11649262B2 (en) | 2015-12-28 | 2023-05-16 | Chugai Seiyaku Kabushiki Kaisha | Method for promoting efficiency of purification of Fc region-containing polypeptide |
BR112018068363A2 (pt) | 2016-03-14 | 2019-01-15 | Chugai Pharmaceutical Co Ltd | fármaco terapêutico indutor de dano celular para uso em terapia de câncer |
CA3026050A1 (en) | 2016-08-05 | 2018-02-08 | Chugai Seiyaku Kabushiki Kaisha | Composition for prophylaxis or treatment of il-8 related diseases |
WO2018203545A1 (ja) | 2017-05-02 | 2018-11-08 | 国立研究開発法人国立精神・神経医療研究センター | Il-6及び好中球の関連する疾患の治療効果の予測及び判定方法 |
US10167396B2 (en) | 2017-05-03 | 2019-01-01 | Corning Incorporated | Low smoke fire-resistant optical ribbon |
KR20200011447A (ko) | 2017-05-30 | 2020-02-03 | 브리스톨-마이어스 스큅 컴퍼니 | 항-lag-3 항체 또는 항-lag-3 항체 및 항-pd-1 또는 항-pd-l1 항체를 포함하는 조성물 |
MX2019012032A (es) | 2017-05-30 | 2019-10-30 | Bristol Myers Squibb Co | Tratamiento de tumores positivos a gen 3 de activacion de linfocitos (lag-3). |
JP2020530440A (ja) | 2017-07-03 | 2020-10-22 | トルク セラピューティクス, インコーポレイテッド | 免疫刺激性融合分子をコードするポリヌクレオチドおよびその使用 |
CN109053892B (zh) | 2018-09-19 | 2021-03-26 | 苏州思坦维生物技术股份有限公司 | 特异结合人及猴cd38抗原的单克隆抗体及其制备方法与应用 |
AU2020258384A1 (en) | 2019-04-15 | 2021-11-04 | Qwixel Therapeutics Llc | Fusion protein composition(s) comprising targeted masked type I interferons (IFNA and IFNB) and an antibody against tumor antigen, for use in the treatment of cancer |
EP4247423A2 (en) | 2020-11-18 | 2023-09-27 | Astrazeneca AB | Steroid sparing |
PT4114465T (pt) | 2021-04-23 | 2023-11-03 | Astrazeneca Ab | Regime de dosagem de anti-ifnar1 para injeção subcutânea |
WO2023006700A1 (en) | 2021-07-27 | 2023-02-02 | Astrazeneca Ab | Treatment of lupus |
JPWO2023120561A1 (hu) * | 2021-12-22 | 2023-06-29 |
Family Cites Families (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4423147A (en) * | 1980-04-11 | 1983-12-27 | Secher David S | Monoclonal antibody to interferon-α |
US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
WO1984003106A1 (en) * | 1983-02-04 | 1984-08-16 | Wadley Inst Of Molecular Medic | Production and characterization of hybridoma antibodies directed specifically against common determinant(s) present among closely related, but distinct proteins |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
FR2560212B1 (fr) * | 1984-02-24 | 1989-12-29 | Unicet | Anticorps monoclonaux contre l'interferon a2 et hybridomes produisant de tels anticorps |
DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4954617A (en) | 1986-07-07 | 1990-09-04 | Trustees Of Dartmouth College | Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes |
US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
US5013653A (en) | 1987-03-20 | 1991-05-07 | Creative Biomolecules, Inc. | Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage |
US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
AU612370B2 (en) | 1987-05-21 | 1991-07-11 | Micromet Ag | Targeted multifunctional proteins |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
ATE135370T1 (de) | 1988-12-22 | 1996-03-15 | Kirin Amgen Inc | Chemisch modifizierte granulocytenkolonie erregender faktor |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
WO1994025585A1 (en) | 1993-04-26 | 1994-11-10 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
EP0814159B1 (en) | 1990-08-29 | 2005-07-27 | GenPharm International, Inc. | Transgenic mice capable of producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
EP0537166B1 (fr) | 1991-04-17 | 1999-07-07 | Medisup International N.V. | Polypeptides hydrosolubles ayant une haute affinite pour les interferons alpha et beta |
JPH0547626A (ja) | 1991-08-09 | 1993-02-26 | Canon Inc | 像投影方法及びそれを用いた半導体デバイスの製造方法 |
DK0601052T3 (da) | 1991-08-30 | 1996-11-18 | Genentech Inc | Terapeutisk fremgangsmåde til behandling af IDDM |
ATE463573T1 (de) | 1991-12-02 | 2010-04-15 | Medimmune Ltd | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
EP0563487A1 (en) | 1992-03-31 | 1993-10-06 | Laboratoire Europeen De Biotechnologie S.A. | Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon |
AU4116793A (en) | 1992-04-24 | 1993-11-29 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
US5821078A (en) * | 1992-09-03 | 1998-10-13 | Yeda Research And Development Co. Ltd. | Nucleic acid encoding interferon-α/β binding protein |
GB9223377D0 (en) | 1992-11-04 | 1992-12-23 | Medarex Inc | Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes |
CA2163345A1 (en) | 1993-06-16 | 1994-12-22 | Susan Adrienne Morgan | Antibodies |
EP0725654A1 (en) | 1993-09-17 | 1996-08-14 | Laboratoire Europeen De Biotechnologie S.A. | Pharmaceutical composition comprising monoclonal antibodies against the interferon receptor, with neutralizing activity against type i interferon |
AU1854695A (en) * | 1994-03-07 | 1995-09-25 | Imperial College Of Science, Technology And Medicine | The use of interferon subtypes in the preparation of medicaments to treat viral infections |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
IL118096A0 (en) | 1996-05-01 | 1996-09-12 | Yeda Res & Dev | Antibodies against interferon alpha/beta receptor |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
AU736549B2 (en) | 1997-05-21 | 2001-08-02 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Method for the production of non-immunogenic proteins |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
ES2434961T5 (es) | 1998-04-20 | 2018-01-18 | Roche Glycart Ag | Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo |
PL209786B1 (pl) | 1999-01-15 | 2011-10-31 | Genentech Inc | Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna |
DK2275540T3 (en) | 1999-04-09 | 2016-05-09 | Kyowa Hakko Kirin Co Ltd | Method for controlling the activity of immunologically functional molecule. |
EP1210372B1 (en) | 1999-07-29 | 2008-01-23 | Medarex, Inc. | Human monoclonal antibodies to her2/neu |
WO2001014424A2 (en) | 1999-08-24 | 2001-03-01 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
CN1324838A (zh) * | 2000-05-24 | 2001-12-05 | 上海博德基因开发有限公司 | 一种新的多肽——人干扰素α受体19.68和编码这种多肽的多核苷酸 |
EP1354034B8 (en) | 2000-11-30 | 2008-06-18 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
US7087726B2 (en) * | 2001-02-22 | 2006-08-08 | Genentech, Inc. | Anti-interferon-α antibodies |
JP2004532038A (ja) | 2001-05-17 | 2004-10-21 | ディヴァーサ コーポレイション | 新規抗原結合分子の治療、診断、予防、酵素、産業ならびに農業各分野への応用とそのための新規抗原結合分子の作製とスクリーニングの方法 |
EP1443961B1 (en) | 2001-10-25 | 2009-05-06 | Genentech, Inc. | Glycoprotein compositions |
CN1416894A (zh) * | 2001-11-09 | 2003-05-14 | 武汉春天生物工程股份有限公司 | 分泌型重组人干扰素α-2a注射液 |
AU2003217912A1 (en) | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
HUE035520T2 (hu) | 2003-12-10 | 2018-05-28 | Squibb & Sons Llc | Interferon alfa antitestek és felhasználásuk |
-
2004
- 2004-12-10 HU HUE11183602A patent/HUE035520T2/hu unknown
- 2004-12-10 SI SI200431998T patent/SI1711207T1/sl unknown
- 2004-12-10 KR KR1020067011437A patent/KR101151477B1/ko not_active IP Right Cessation
- 2004-12-10 CN CN201110220119.6A patent/CN102344491B/zh active Active
- 2004-12-10 CN CNA2004800367759A patent/CN1889978A/zh active Pending
- 2004-12-10 NZ NZ547157A patent/NZ547157A/xx unknown
- 2004-12-10 JP JP2006544092A patent/JP5047626B2/ja not_active Expired - Fee Related
- 2004-12-10 AU AU2004299833A patent/AU2004299833B2/en not_active Ceased
- 2004-12-10 PT PT48140156T patent/PT1711207E/pt unknown
- 2004-12-10 PT PT111836029T patent/PT2418220T/pt unknown
- 2004-12-10 EP EP11183602.9A patent/EP2418220B1/en active Active
- 2004-12-10 EP EP04814015A patent/EP1711207B1/en active Active
- 2004-12-10 ES ES11183602.9T patent/ES2641831T3/es active Active
- 2004-12-10 KR KR1020117028318A patent/KR101225299B1/ko not_active IP Right Cessation
- 2004-12-10 LT LTEP11183602.9T patent/LT2418220T/lt unknown
- 2004-12-10 IN IN2655KON2009 patent/IN2009KN02655A/en unknown
- 2004-12-10 DK DK04814015.6T patent/DK1711207T3/da active
- 2004-12-10 SI SI200432410T patent/SI2418220T1/sl unknown
- 2004-12-10 WO PCT/US2004/041777 patent/WO2005059106A2/en active Application Filing
- 2004-12-10 CA CA2546054A patent/CA2546054C/en not_active Expired - Fee Related
- 2004-12-10 PL PL11183602T patent/PL2418220T3/pl unknown
- 2004-12-10 US US11/009,410 patent/US7741449B2/en active Active
- 2004-12-10 PL PL04814015T patent/PL1711207T3/pl unknown
- 2004-12-10 DK DK11183602.9T patent/DK2418220T3/da active
- 2004-12-10 ES ES04814015T patent/ES2399050T3/es active Active
-
2006
- 2006-05-11 IL IL175586A patent/IL175586A/en not_active IP Right Cessation
-
2007
- 2007-04-02 HK HK07103513.5A patent/HK1095765A1/xx not_active IP Right Cessation
-
2009
- 2009-08-06 AU AU2009206187A patent/AU2009206187B2/en not_active Ceased
- 2009-08-31 US US12/551,250 patent/US8025882B2/en active Active
-
2010
- 2010-11-30 JP JP2010267571A patent/JP2011097943A/ja active Pending
-
2011
- 2011-08-16 US US13/211,092 patent/US8475797B2/en active Active
-
2013
- 2013-06-04 US US13/909,608 patent/US8722870B2/en active Active
-
2014
- 2014-03-21 US US14/222,039 patent/US9765141B2/en active Active
-
2017
- 2017-08-14 US US15/676,552 patent/US20170369568A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11072664B2 (en) | Interferon receptor 1 antibodies and their uses | |
US9765141B2 (en) | Methods for preparing interferon alpha antibodies | |
AU2012203451B2 (en) | Interferon alpha antibodies and their uses | |
AU2011236019B2 (en) | Interferon alpha receptor 1 antibodies and their uses |